Pirtobrutinib, a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed promising efficacy in patients with previously treated mantle cell lymphoma (MCL), according to updated data from the phase I/II BRUIN study, presented at the 2021...